Nasdaq
$1.48▲ 0.68%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $39.3MShares out 26.6M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
8- 3d agoPre-market26.10.21 22:008-KKey event#●●●#●●●#●●●
Inmune Bio, Inc.Bullish
Inmune Bio has entered into a Master Services Agreement with Uniphar to support the international commercialization of its RDEB therapy, Ebstrocel. Additionally, the company submitted its final pre-MAA package to the UK MHRA, targeting a full MAA submission in February 2027 and potential UK approval by mid-2027.…more
$1.48+0.68%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.23Pre-market26.09.23 19:054Ownership
Inmune Bio, Inc.
Inmune Bio, Inc. insider Clark Ronnie Duane reported a change in beneficial ownership of securities effective September 15, 2026. This filing serves as the official Form 4 disclosure of the insider's equity transaction.…more
$1.48+0.68%vs prev closeView filingShare - 9.23Pre-market26.09.23 19:023Ownership
Inmune Bio, Inc.
Inmune Bio, Inc. insider Ronnie Duane Clark has filed a Form 3, reporting his initial statement of beneficial ownership of securities as of September 8, 2026. This filing serves as an official disclosure of the insider's equity holdings to the market.…more
$1.48+0.68%vs prev closeView filingShare
7 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 4d agoPre-market26.10.21 20:18#●●●#●●●
INmune Bio Submits Final Pre-MAA Package to UK MHRA for Ebstrocel
INmune Bio has submitted its final pre-MAA package to the UK MHRA, aiming for potential approval of its RDEB therapy Ebstrocel by mid-2027. The company is also coordinating with the FDA to submit a BLA in the second quarter of 2027.…more
$1.48+0.68%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 4d agoPre-market26.10.21 20:02
●●●●●●●● ●●●●● ●●●●●●
INmune Bio has entered into a master services agreement with Uniphar to provide named-patient access to Ebstrocel in select European and MENA markets. The agreement lacks specific financial details, leading to a neutral outlook.…more
$1.48+0.68%vs prev closeShareBenzinga - 10.14Pre-market26.10.14 21:35
●●●●●●●● ●●●●● ●●●●●●
INmune Bio and Quantum Computing Inc. have partnered to apply quantum AI to identify new treatment applications and biomarkers for the Alzheimer's drug XPro. While this marks QCi's first commercial customer in the biotech sector, the collaboration is in its early stages without specific financial terms or guaranteed outcomes.…more
$1.48+0.68%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report